EQUITY RESEARCH - RESULTS FLASH







TARGET PRICE

UP/DOWNSIDE

TP vs CONSENSUS

CLOSE

BDMS TB



THB35.00

THB29.50

+18.6%

0.0%

BANGKOK DUSIT MEDICAL SERVICES THAILAND / HEALTH CARE SERVICES

1Q24 results at first glance

BDMS รายงานกำไรปกติทำสถิติสูงสุดใหม่ที่ 4.0พัน ลบ. ใกล้เคียงกับที่เรา คาด

Highlights

- BDMS รายงานกำไรปกติทำสถิติสูงสุดใหม่ที่ 4.0พัน ลบ. ใน 1Q24 (+17% y-y, +3% qq) ใกล้เคียงกับที่เราและตลาดคาด
- รายได้จากธุรกิจโรงพยาบาลโต 11% y-y เป็น 25.5พัน ลบ. ทำสถิติสูงสุดใหม่ รายได้ จากผู้ป่วยต่างชาติโต 12% y-y โดยได้ปัจจัยผลักดันจากรายได้จากผู้ป่วยจากประเทศจีน (+45% y-y) ฝรั่งเศส (+29% y-y) และสหรัฐฯ (+19% y-y) ในขณะที่รายได้จากผู้ป่วย ชาวไทยโต 10% y-y ในไตรมาสนี้
- ต้นทุนขายเพิ่ม 11% y-y ในขณะที่ค่าใช้จ่ายการขายและบริหารเพิ่ม 6% y-y ซึ่งทำให้ EBITDA margin ปรับตัวดีขึ้นเป็น 25.2% (เทียบกับ 24.6% ใน 1Q23 และ 24.9% ใน 4Q23) นอกจากนี้ถ้าไม่รวมช่วงที่โควิดแพร่ระบาด EBITDA margin ก็ทำสถิติสูงสุดใหม่ ด้วย
- ี กำไรปกติ 1Q24 คิดเป็น 25% ของประมาณการกำไรปกติปี 2024 ของเราที่ 16.4พัน ลาเ

Outlook

เราคาดว่ารายได้จะมี Momentum การเติบโตต่อเนื่อง y-y ใน 2Q24 โดยได้ปัจจัยหนุน จากการเติบโตภายในที่อยู่ในเกณฑ์ดี นอกจากนี้รายได้จากผู้ป่วยต่างชาติก็น่าจะเพิ่มขึ้น โดยมีสมมติฐานจากผลกระทบของเทศกาลรอมฏอนที่น้อยลงใน 2Q24 เทียบกับ 2Q23 (เทศกาลรอมภูอนเริ่มตั้งแต่วันที่ 10 มี.ค. ถึง 9 เม.ย. 2024 เทียบกับ 22 มี.ค. - 21 เม.ย. 2023)

KEY STOCK DATA

YE Dec (THB m)	2023	2024E	2025E	2026E
Revenue	102,110	112,311	121,304	131,022
Net profit	14,375	16,413	17,928	19,652
EPS (THB)	0.90	1.03	1.13	1.24
vs Consensus (%)	-	4.7	5.3	4.9
EBITDA	24,740	27,717	30,179	32,859
Recurring net profit	14,375	16,413	17,928	19,652
Core EPS (THB)	0.90	1.03	1.13	1.24
EPS growth (%)	14.0	14.2	9.2	9.6
Core P/E (x)	32.6	28.6	26.1	23.9
Dividend yield (%)	2.2	2.4	2.5	2.7
EV/EBITDA (x)	19.4	17.3	15.7	14.3
Price/book (x)	4.9	4.7	4.4	4.1
Net debt/Equity (%)	8.8	6.2	1.1	(3.9)
ROE (%)	15.5	16.8	17.3	17.8



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	6.3	5.4	(0.8)
Relative to country (%)	7.8	6.0	12.5
Mkt cap (USD m)			12,786
3m avg. daily turnover (USD m))		30.6
Free float (%)			70
Major shareholder	Prasert Pra	asarttong-O	soth (13%)
12m high/low (THB)		3	0.00/25.00
Issued shares (m)			15,892.00

Sources: Bloomberg consensus; FSSIA estimates



Teerapol Udomvej, CFA Fundamental Investment Analyst on Securities; License no. 080523 teerapol.udo@fssia.com, +66 2646 9969

PREPARED BY FSS INTERNATIONAL INVESTMENT ADVISORY SECURITIES CO LTD (FSSIA). ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES CAN BE FOUND AT THE END OF THIS REPORT

Exhibit 1: BDMS - 1Q24 results summary

	1Q23	2Q23	3Q23	4Q23	1Q24	Cha	nge	2023	2024E	Change
	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(у-у %				
Sales	24,313	24,372	26,699	26,726	26,930	1	11	102,110	112,311	-
- Hospital revenue	23,084	23,141	25,473	25,379	25,526	1	11	97,077	106,875	
- Other revenue	1,229	1,232	1,227	1,346	1,404	4	14	5,034	5,436	
COGS (incl depreciation)	(15,122)	(15,432)	(16,469)	(16,389)	(16,736)	2	11	(63,412)	(69,333)	
Gross profit	9,191	8,940	10,230	10,337	10,194	(1)	11	38,698	42,979	1
SG&A	(4,633)	(4,876)	(5,106)	(5,191)	(4,893)	(6)	6	(19,806)	(21,504)	
Operating profit ¹⁾	4,558	4,064	5,124	5,146	5,301	3	16	18,892	21,475	
Net other income	12	5	7	19	9	(52)	(25)	43	48	
Interest income	26	48	48	52	48	(7)	87	173	110	(3
Interest expense	(164)	(134)	(122)	(126)	(113)	(11)	(31)	(547)	(501)	(
Pretax profit	4,432	3,983	5,057	5,091	5,246	3	18	18,563	21,131	1
Income Tax	(880)	(812)	(1,025)	(1,038)	(1,042)	0	18	(3,755)	(4,226)	1
Associates	34	13	21	22	13	(41)	(62)	89	98	1
Minority interest	(116)	(120)	(163)	(123)	(143)	16	23	(522)	(590)	1
Core profit	3,470	3,063	3,890	3,952	4,074	3	17	14,375	16,413	1
Extraordinaries, GW & FX	ŕ	,	•	•	•			0	0	
Reported net profit	3,470	3,063	3,890	3,952	4,074	3	17	14,375	16,413	1
Outstanding shares (m)	15,892	15,892	15,892	15,892	15,892	0	0	15,892	15,892	
Core EPS (THB)	0.22	0.19	0.24	0.25	0.26	3	17	0.90	1.03	
EPS (THB)	0.22	0.19	0.24	0.25	0.26	3	17	0.90	1.03	
21 3 (1112)	0.22	0.13	0.24	0.23	0.20	J	.,	0.50	1.00	
COGS (excl depreciation)	13,693	13,986	14,999	14,886	15,259	3	11	57,564	63,090	
Depreciation	1,429	1,446	1,470	1,503	1,477	(2)	3	5,848	6,243	
EBITDA ²⁾	5,987	5,510	6,594	6,649	6,778	2	13	24,740	27,717	
Key ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)	(pr
Gross margin	38	37	38	38.7	37.9	(1)	0	38	38	
SG&A/Revenue	19	20	19	19	18	(1)	(1)	19	19	(
EBITDA margin	24.6	22.6	24.7	24.9	25.2	0	1	24	25	
Net profit margin	14	13	15	15	15	0	1	14	15	
Operating stats	(%)	(%)	(%)	(%)	(%)					
OPD revenue growth y-y	11	10	14	10	12					
OPD volume growth y-y	(7)	0	0							
OPD revenue per head growth y-y	20	10	14							
IPD revenue growth y-y	(2)	10	9	15	9					
IPD volume growth y-y	33	60	20							
IPD revenue per head growth y-y	(26)	(31)	(9)							
Thai revenue growth y-y	(6)	7	9	10	10					
	(-)	-	_							

Note: 1) Gross profit calculated by revenue – COGS including depreciation; 2) EBITDA calculated by operating profit + operating income – depreciation Sources: BDMS; FSSIA estimates

Exhibit 2: International patient revenue





Exhibit 3: Thai patient revenue



Source: BDMS Source: BDMS

Financial Statements

Bangkok Dusit Medical Services

Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Revenue	92,968	102,110	112,311	121,304	131,022
Cost of goods sold	(58,329)	(63,412)	(69,333)	(74,787)	(80,610)
Gross profit	34,638	38,698	42,979	46,518	50,413
Other operating income	· -	-	· -	-	· -
Operating costs	(17,655)	(19,806)	(21,504)	(23,104)	(24,824)
Operating EBITDA	22,933	24,740	27,717	30,179	32,859
Depreciation	(5,950)	(5,848)	(6,243)	(6,766)	(7,271)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	16,984	18,892	21,475	23,413	25,588
Net financing costs	(552)	(373)	(391)	(358)	(288)
Associates	42	89	98	108	119
Recurring non-operating income	50	133	146	161	177
Non-recurring items	0	0	0	0	0
Profit before tax	16,481	18,652	21,230	23,216	25,477
Tax	(3,227)	(3,755)	(4,226)	(4,622)	(5,072)
Profit after tax	13,254	14,897	17,003	18,595	20,406
Minority interests	(648)	(522)	(590)	(667)	(753)
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	12,606	14,375	16,413	17,928	19,652
Non-recurring items & goodwill (net)	0	0	0	0	0
Recurring net profit	12,606	14,375	16,413	17,928	19,652
Per share (THB)					
Recurring EPS *	0.79	0.90	1.03	1.13	1.24
Reported EPS	0.79	0.90	1.03	1.13	1.24
DPS	0.50	0.65	0.70	0.72	0.79
Diluted shares (used to calculate per share data)	15,892	15,892	15,892	15,892	15,892
Growth			40.0		
Revenue (%)	23.1	9.8	10.0	8.0	8.0
Operating EBITDA (%)	32.2	7.9	12.0	8.9	8.9
Operating EBIT (%)	54.1	11.2	13.7	9.0	9.3
Recurring EPS (%)	63.0	14.0	14.2 14.2	9.2 9.2	9.6
Reported EPS (%)	58.8	14.0	14.2	9.2	9.6
Operating performance	27.2	27.0	20.2	20.2	20 5
Gross margin inc. depreciation (%)	37.3	37.9	38.3	38.3	38.5
Gross margin exc. depreciation (%)	43.7 24.7	43.6 24.2	43.8 24.7	43.9 24.9	44.0 25.1
Operating EBITDA margin (%) Operating EBIT margin (%)	18.3	18.5	19.1	19.3	19.5
Net margin (%)	13.6	14.1	14.6	14.8	15.0
Effective tax rate (%)	19.6	20.2	20.0	20.0	20.0
Dividend payout on recurring profit (%)	63.0	71.9	67.8	64.1	63.9
Interest cover (X)	30.8	51.0	55.3	65.9	89.5
Inventory days	14.7	14.7	14.7	14.8	14.8
Debtor days	38.5	39.4	37.6	34.8	32.2
Creditor days	39.1	41.5	41.8	42.2	42.2
Operating ROIC (%)	15.8	16.1	17.5	18.6	19.9
ROIC (%)	12.7	13.1	14.4	15.3	16.5
ROE (%)	14.5	15.5	16.8	17.3	17.8
ROA (%)	10.1	10.7	11.8	12.2	12.7
* Pre exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2022	2023	2024E	2025E	2026E
Thai patient revenue	67,286	70,866	76,733	82,741	89,217
International patient revenue	21,248	26,211	30,142	32,855	35,812
Other revenue	4,433	5,034	5,436	5,708	5,993
Sources: Pangkok Dusit Medical Sonriges: ESSIA actima		/==	,	,	.,

Sources: Bangkok Dusit Medical Services; FSSIA estimates

Financial Statements

Bangkok Dusit Medical Services

Bangkok Dusit Medical Services					
Cash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Recurring net profit	12,606	14,375	16,413	17,928	19,652
Depreciation	5,950	5,848	6,243	6,766	7,271
Associates & minorities	5,950	3,040	0,243	0,700	7,271
Other non-cash items	1,275	1,203	590	667	753
Change in working capital	720	161	1,291	1,142	1,234
Cash flow from operations	20,551	21,588	24,537	26,503	28,910
Capex - maintenance	(14,953)	(11,612)	(11,231)	(9,704)	(10,482)
Capex - new investment	-	-	-	-	-
Net acquisitions & disposals	(386)	(290)	0	0	0
Other investments (net)	-	-	-	-	-
Cash flow from investing	(15,340)	(11,902)	(11,231)	(9,704)	(10,482)
Dividends paid	(7,943)	(10,343)	(11,124)	(11,489)	(12,550)
Equity finance	0	0	0	0	0
Debt finance	4,764	(5,460)	(500)	(500)	(500)
Other financing cash flows	299	612	0	0	0
Cash flow from financing	(2,880)	(15,190)	(11,624)	(11,989)	(13,050)
Non-recurring cash flows	-	-	-	-	-
Other adjustments	0	0	0	0	0
Net other adjustments	0	0	0	0	0
Movement in cash	2,330	(5,505)	1,681	4,810	5,379
Free cash flow to firm (FCFF)	5,842.84	10,232.29	13,806.49	17,285.67	18,901.18
Free cash flow to equity (FCFE)	10,273.66	4,838.23	12,805.74	16,298.92	17,928.43
Per share (THB)					
FCFF per share	0.37	0.64	0.87	1.09	1.19
FCFE per share	0.65	0.30	0.81	1.03	1.13
Recurring cash flow per share	1.25	1.35	1.46	1.60	1.74
Balance Sheet (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Tangible fixed assets (gross)	155,412	165,315	176,546	186,250	196,732
Less: Accumulated depreciation	(63,503)	(67,642)	(73,884)	(80,650)	(87,921)
Tangible fixed assets (net)	91,909	97,673	102,662	105,600	108,811
Intangible fixed assets (net)	19,160	19,376	19,376	19,376	19,376
Long-term financial assets	-	-	-	-	-
Invest. in associates & subsidiaries	1,986	2,276	2,276	2,276	2,276
Cash & equivalents	14,972	9,467	11,148	15,958	21,337
A/C receivable	10,484	11,558	11,558	11,558	11,558
Inventories	2,211	2,420	2,652	2,859	3,083
Other current assets	132	101	111	120	130
Current assets	27,799	23,545	25,469	30,495	36,107
Other assets	689	726	726	726	726
Total assets	141,543	143,596	150,508	158,472	167,295
Common equity	89,879	95,242	100,531	106,970	114,072
Minorities etc.	3,834	3,630	4,220	4,887	5,641
Total shareholders' equity	93,713	98,872	104,752	111,857	119,713
Long term debt	23,062	18,134	17,634	17,134	16,634
Other long-term liabilities	10,032	10,973	10,973	10,973	10,973
Long-term liabilities A/C payable	33,094 6,176	29,107 6,901	28,607 7,564	28,107 8,155	27,607 8,792
Short term debt	532	0,901	7,304	0,133	0,792
Other current liabilities	8,028	8,715	9,586	10,353	11,183
Current liabilities	14,736	15,616	17,149	18,508	19,975
Total liabilities and shareholders' equity	141,543	143,596	150,508	158,472	167,295
Net working capital	(1,377)	(1,538)	(2,828)	(3,971)	(5,205)
Invested capital	112,367	118,513	122,211	124,006	125,984
* Includes convertibles and preferred stock which is be		110,010	122,211	12-1,000	120,001
<u> </u>					
Per share (THB)					
Book value per share	5.66	5.99	6.33	6.73	7.18
Tangible book value per share	4.45	4.77	5.11	5.51	5.96
Financial strength					
Net debt/equity (%)	9.2	8.8	6.2	1.1	(3.9)
Net debt/total assets (%)	6.1	6.0	4.3	0.7	(2.8)
Current ratio (x)	1.9	1.5	1.5	1.6	1.8
CF interest cover (x)	19.6	14.0	33.7	46.6	63.3
	2022	2023	2024E	2025E	2026E
Valuation	LVLL				
		30 5	20 C	26.4	
Recurring P/E (x) *	37.2	32.6 38.7	28.6 33.0	26.1 31.0	23.9
Recurring P/E (x) * Recurring P/E @ target price (x) *	37.2 44.1	38.7	33.9	31.0	28.3
Recurring P/E (x) * Recurring P/E @ target price (x) * Reported P/E (x)	37.2 44.1 37.2	38.7 32.6	33.9 28.6	31.0 26.1	28.3 23.9
Recurring P/E (x) * Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%)	37.2 44.1 37.2 1.7	38.7 32.6 2.2	33.9 28.6 2.4	31.0 26.1 2.5	28.3 23.9 2.7
Recurring P/E (x) * Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%) Price/book (x)	37.2 44.1 37.2 1.7 5.2	38.7 32.6 2.2 4.9	33.9 28.6 2.4 4.7	31.0 26.1 2.5 4.4	28.3 23.9 2.7 4.1
Valuation Recurring P/E (x) * Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%) Price/book (x) Price/tangible book (x) EV/EBITDA (x) **	37.2 44.1 37.2 1.7 5.2 6.6	38.7 32.6 2.2 4.9 6.2	33.9 28.6 2.4 4.7 5.8	31.0 26.1 2.5 4.4 5.4	28.3 23.9 2.7 4.1 5.0
Recurring P/E (x) * Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%) Price/book (x) Price/tangible book (x) EV/EBITDA (x) **	37.2 44.1 37.2 1.7 5.2 6.6 21.0	38.7 32.6 2.2 4.9 6.2 19.4	33.9 28.6 2.4 4.7 5.8 17.3	31.0 26.1 2.5 4.4 5.4 15.7	28.3 23.9 2.7 4.1 5.0 14.3
Recurring P/E (x) * Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%) Price/book (x) Price/tangible book (x)	37.2 44.1 37.2 1.7 5.2 6.6	38.7 32.6 2.2 4.9 6.2	33.9 28.6 2.4 4.7 5.8	31.0 26.1 2.5 4.4 5.4	28.3 23.9 2.7 4.1 5.0

Sources: Bangkok Dusit Medical Services; FSSIA estimates

Bangkok Dusit Medical Serv (BDMS TB)

FSSIA ESG rating

★ ★ ★ ★

Exhibit 4: FSSIA ESG score implication

74.00 /100

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
****	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

Exhibit 5: ESG – peer comparison

	FSSIA			Domes	stic ratings	;				Glo	bal ratings	;		Bloomberg	
	ESG score	DJSI	SET THSI	THSI	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
всн	39.71				4.00	5.00	Certified	High	48.21			27.19	18.00	3.52	47.60
BDMS	74.00	Υ	Y	Y	5.00	4.00		Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92
BH	51.21				4.00	4.00		Medium	64.29	Α	29.00	59.03	27.00	5.08	47.79
CHG	38.25				4.00	5.00		High	55.35			59.57	21.00	2.34	50.24
PR9	54.08		Υ	Υ	5.00	5.00	Certified	High	71.12			62.39		2.43	37.90
PRINC	18.00				4.00	4.00	Certified								
RAM	11.75				3.00			High							
THG	18.75				5.00	5.00		High							
VIBHA	20.88				4.00	3.00	Declared	High					17.00		

Sources: <u>SETTRADE.com</u>; FSSIA's compilation

Exhibit 6: ESG score by Bloomberg

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	1.08	1.05	2.21	2.76	3.74	3.77	3.76	3.45
BESG environmental pillar score	0.00	0.00	2.04	4.49	4.17	3.84	3.24	2.25
BESG social pillar score	0.14	0.14	1.24	1.48	3.40	3.53	3.54	3.59
BESG governance pillar score	4.56	4.40	4.37	4.19	4.03	4.13	4.51	4.12
ESG disclosure score	32.33	32.33	46.90	47.34	57.35	57.69	58.34	58.92
Environmental disclosure score	0.00	0.00	22.74	24.07	52.31	52.31	54.27	56.00
Social disclosure score	13.21	13.21	34.22	34.22	36.03	37.06	37.06	37.06
Governance disclosure score	83.59	83.59	83.59	83.59	83.59	83.59	83.59	83.59
Environmental								
Emissions reduction initiatives	No							
Climate change policy	No	No	No	No	Yes	Yes	Yes	Yes
Climate change opportunities discussed	No							
Risks of climate change discussed	No							
GHG scope 1	_	_	3	4	9	35	9	34
GHG scope 2 location-based	_	_	91	92	98	94	96	209
GHG Scope 3	_	_	_	_	_	_	_	_
Carbon per unit of production	_	_	_	_	_	_	_	_
Biodiversity policy	No							
Energy efficiency policy	No	No	Yes	Yes	Yes	Yes	Yes	Yes
Total energy consumption	_	_	143	145	152	147	194	497
Renewable energy use	_	_	_	_	_	_	_	5
Electricity used	_	_	143	145	152	147	192	417
Fuel used - natural gas	_	_	_	_	_	_	_	

Sources: Bloomberg; FSSIA's compilation

Exhibit 7: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No	No	No	No	No	No	No	No
Waste reduction policy	No	No	No	Yes	Yes	Yes	Yes	Yes
Hazardous waste	_	_	1	2	2	2	3	5
Total waste	_	_	6	7	7	5	9	13
Waste recycled	_	_	0	1	1	0	1	2
Waste sent to landfills	_	_	_	_	_	_	3	5
Environmental supply chain management	No	No	No	No	Yes	Yes	Yes	Yes
Water policy	No	No	No	Yes	Yes	Yes	Yes	Yes
Water consumption	_	_	354	358	388	332	472	754
Social								
Human rights policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Policy against child labor	No	No	No	No	No	Yes	Yes	Yes
Quality assurance and recall policy	No	No	No	No	Yes	Yes	Yes	Yes
Consumer data protection policy	No	No	Yes	Yes	Yes	Yes	Yes	Yes
Equal opportunity policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Gender pay gap breakout	No	No	No	No	No	No	No	No
Pct women in workforce	_	_	82	82	82	82	83	83
Pct disabled in workforce	_	_	_	_	_	_	_	_
Business ethics policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Anti-bribery ethics policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Health and safety policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Lost time incident rate - employees	_	_	0	0	0	0	0	1
Total recordable incident rate - employees	_	_	2	2	2	1	1	1
Training policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Fair remuneration policy	No	No	No	No	No	No	No	No
Number of employees – CSR	33,456	36,989	37,505	38,803	40,298	36,254	36,344	40,495
Employee turnover pct			18	19	19	17	16	20
Total hours spent by firm - employee training	568,960	588,890	795,330	547,592	784,625	476,816	437,209	1,417,320
Social supply chain management	No	No	No	No	Yes	Yes	Yes	Yes
Governance	140	140	140	110	100	100	100	100
Board size	15	14	13	14	14	16	18	17
No. of independent directors (ID)	7	6	6	6	6	7	7	7
No. of women on board	2	1	1	1	1	2	2	2
No. of non-executive directors on board	9	7	6	8	9	9	9	9
Company conducts board evaluations	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
No. of board meetings for the year	13	13	14	12	13	12	12	12
Board meeting attendance pct	95	94	98	97	98	98	97	100
Board duration (years)	3	3	3	3	3	3	3	3
						No		No
Director share ownership guidelines	No 45	No 42	No 42	No 44	No 45		No	
Age of the youngest director	45	42 84	43	44	45 97	46	47	48
Age of the oldest director	83	5 5	85 5	86	87	88 7	89 -	90
No. of executives / company managers	4			5	6	7	5	5
No. of female executives	1	1 N-	1 N-	2	1 N-	2	2	2
Executive share ownership guidelines	No	No	No	No	No	No	No	No
Size of audit committee	3	3	3	3	3	3	3	3
No. of ID on audit committee	3	3	3	3	3	3	3	3
Audit committee meetings	10	9	10	7	10	6	6	6
Audit meeting attendance %	100	100	100	100	97	100	100	100
Size of compensation committee	4	4	4	4	4	3	3	3
No. of ID on compensation committee	3	3	3	2	2	2	2	2
No. of compensation committee meetings	3	1	4	4	3	4	4	3
Compensation meeting attendance %	100	100	100	100	100	100	100	100
Size of nomination committee	4	4	4	4	4	3	3	3
No. of nomination committee meetings	3	1	4	4	3	4	4	3
Nomination meeting attendance %	100	100	100	100	100	100	100	100
Sustainability governance								
Verification type	No	No	No	No	No	No	No	No

Sources: Bloomberg; FSSIA's compilation

Disclaimer for ESG scoring

ESG score	Methodolo	gy			Rating				
The Dow Jones Sustainability Indices (DJSI) By S&P Global	process bas from the an	sed on the con nual S&P Glob	transparent, rules-based npanies' Total Sustainabil oal Corporate Sustainabili nanies within each industr	ity Scores resulting ty Assessment (CSA).	Sustainability A ESG Score of I scoring compa selected from t	ssessment (C ess than 45% ny are disqual he Eligible Un		ompanies with al ESG Score uents of the D	an S&P Globa of the highest JSI indices are
Sustainability nvestment List (THSI) yoy The Stock Exchange of Thailand SET)	managing b Candidates 1) no irregu float of >150 up capital. S 70%; 2) ind wrongdoing	nusiness with to must pass the lar trading of the 0 shareholders Some key disquependent direct related to CG	ility in Environmental and ransparency in Governan- e preemptive criteria, with he board members and exis, and combined holding rualifying criteria include: 'ctors and free float violation, social & environmental iteramings in red for > 3 years	ce, updated annually. two crucial conditions: kecutives; and 2) free nust be >15% of paid- 1) CG score of below on; 3) executives' mpacts; 4) equity in	minimum of 50 during the assenture of the research serious capitalization >>0.5% of paid-Index is a mark	% for each incessment year. elevant industres is extended THB5b (~US) up capital for a cet capitalisation.	sion, verified dat dicator, unless th. The scoring will y and materiality from the THSI or D150b); 2) free flat least 9 out of 1 on-weighted indember of stocks.	e company is be fairly weigh ompanies who oat >20%; and 2 months. The	a part of DJSI nted against th se 1) market d 3) liquidity e SETTHSI
CG Score by Thai nstitute of Directors Association Thai IOD)	annually by Thailand (S	the Thai IOD,	th in sustainable developr with support from the Sto Its are from the perspectives.	ck Exchange of	Good (80-89), and not rated f equitable treati	3 for Good (70 or scores belo nent of shareh 25%); 4) disclo	ories: 5 for Excel 0-79), 2 for Fair (0 w 50. Weightings nolders (weight 2 osure & transpare	60-69), 1 for P s include: 1) th 5% combined	ass (60-69), ne rights; 2) an); 3) the role o
AGM level By Thai nvestors Association TIA) with support from he SEC	treatment a transparent out of five th criteria cove date (45%), circulation of exercised. Th and verifiabilii	re incorporated and sufficiently and sufficiently and after the sufficient informate second assessity; and 3) openned	which shareholders' rights d into business operations by disclosed. All form imponents to be evaluated annures before the meeting meeting (10%). (The first a station for voting; and 2) facilitating sess 1) the ease of attending mees for Q&A. The third involveues, resolutions and voting res	s and information is ortant elements of two ually. The assessment (45%), at the meeting ssesses 1) advance ing how voting rights can be eletings; 2) transparency is the meeting minutes that			o four categories: r (80-89), and no		
Fhai CAC By Thai Private Sector Collective Action Against Corruption CAC)	establishme policies. The (Companies of Declaration of Certification, I managers and	ent of key control e Certification deciding to becor f Intent to kick of including risk ass	Checklist include corrupti- rols, and the monitoring a is good for three years. The a CAC certified member si of an 18-month deadline to sub- sessment, in place of policy at tablishment of whistleblowing that stakeholders.)	nd developing of tart by submitting a mit the CAC Checklist for and control, training of	passed Checkl	ist will move fo se members a	ed by a committe or granting certifi are twelve highly achievements.	cation by the 0	CAC Council
Morningstar Bustainalytics	based on an risk is unma regulatory filir	n assessment anaged. Source ngs, news and ot	isk rating provides an ove of how much of a compar as to be reviewed include corp ther media, NGO reports/webs	ny's exposure to ESG orate publications and sites, multi-sector	more risk is un	managed, the	score is the sum higher ESG risk	is scored.	
		ompany feedbac quality & peer rev	ck, ESG controversies, issuer views.	feedback on draft ESG	NEGL 0-10	Low 10-20	Medium 20-30	High 30-40	Severe 40+
ESG Book	positioned t the principle helps explai over-weight	o outperform on the of financial main future risk-a	sustainable companies the over the long term. The materiality including inform djusted performance. Matith higher materiality and erly basis.	ethodology considers ation that significantly teriality is applied by	The total ESG scores using m	score is calcul ateriality-base	lated as a weight ed weights. The s ndicating better p	ed sum of the	features
<u>MSCI</u>			measure a company's mand laggards according to						nethodology to
	AAA	8.571-10.00	Leader:	leading its industry in m	anaging the most s	gnificant ESG ri	sks and opportunitie	es	
	AA	7.143-8.57							
	A BBB	5.714-7.14: 4.286-5.71;		a mixed or unexception	al track record of m	anaging the mos	st significant ESG ris	sks and opportu	nities relative to
	BB	2.857-4.28	_	industry peers					
	В	1.429-2.850							
	ccc	0.000-1.428	Laggard:	lagging its industry base	ed on its high expos	ure and failure t	o manage significar	nt ESG risks	
Moody's ESG			gree to which companies	take into account ESG o	bjectives in the o	efinition and in	mplementation of	f their strategy	policies. It
olutions	believes tha	at a company i	ntegrating ESG factors into for shareholders over the	to its business model and					
Refinitiv ESG ating	based on pu	ublicly availabl	and objectively measure e and auditable data. The ata publicly. (Score ratings a	score ranges from 0 to	100 on relative E	SG performar	nce and insufficie	nt degree of t	
S&P Global			ore is a relative score meanin the same industry clas				of ESG risks, op	portunities, ar	id impacts
Dia anni anni	ESG Score			ating the company's aggrapherg's view of ESG fina					
Bloomberg				the weights are determin	ed by the pillar p	riority ranking	. Values range fr		is the best.

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price



Date	Rating	Target price	Date	Rating	Target price	Date	Rating	Target price
24-Jun-2021 19-Apr-2022	BUY BUY	29.00 31.00	06-Oct-2022 08-Jan-2023	BUY BUY	33.00 34.50	18-Jan-2024	BUY	35.00

Teerapol Udomvej, CFA started covering this stock from 30-Jul-2020

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Bangkok Dusit Medical Services	BDMS TB	THB 29.50	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher-than-expected capex and opex for CoE projects.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 14-May-2024 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.